Bifogade filer
PDF
Kurs
-7,14%
Likviditet
1 070 MSEK
Kalender
| Est. tid* | ||
| 2026-02-18 | 08:00 | Bokslutskommuniké 2025 |
| 2025-11-13 | 01:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-28 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-23 | - | X-dag ordinarie utdelning BIOA B 0.00 SEK |
| 2025-05-22 | - | Årsstämma |
| 2025-05-21 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-13 | - | Bokslutskommuniké 2024 |
| 2024-11-14 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-23 | - | X-dag ordinarie utdelning BIOA B 0.00 SEK |
| 2024-05-22 | - | Årsstämma |
| 2024-05-17 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-11-08 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-12 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-02 | - | X-dag ordinarie utdelning BIOA B 0.00 SEK |
| 2023-06-01 | - | Årsstämma |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-03 | - | Bokslutskommuniké 2022 |
| 2022-10-20 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-12 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | - | X-dag ordinarie utdelning BIOA B 0.00 SEK |
| 2022-05-05 | - | Årsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-03 | - | Bokslutskommuniké 2021 |
| 2021-10-21 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-09 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-07 | - | X-dag ordinarie utdelning BIOA B 0.00 SEK |
| 2021-05-06 | - | Årsstämma |
| 2021-04-21 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-04 | - | Bokslutskommuniké 2020 |
| 2020-10-14 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-10 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-08 | - | X-dag ordinarie utdelning BIOA B 0.00 SEK |
| 2020-05-07 | - | Årsstämma |
| 2020-04-22 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-06 | - | Bokslutskommuniké 2019 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-11 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-10 | - | X-dag ordinarie utdelning BIOA B 1.50 SEK |
| 2019-05-09 | - | Årsstämma |
| 2019-05-09 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-08 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-16 | - | X-dag ordinarie utdelning BIOA B 0.00 SEK |
| 2018-05-15 | - | Årsstämma |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-20 | - | Bokslutskommuniké 2017 |
| 2017-11-08 | - | Kvartalsrapport 2017-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, September 3, 2025 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has been made aware that the company's two founders and main shareholders, Lars Lannfelt and Pär Gellerfors, intend to divest a minor part of their respective shareholding.
---
This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on September 3, 2025, at 5:35 p.m. CET.
For further information, please contact:
Oskar Bosson, Vice President Communications and Investor Relations
E-mail: [email protected]
Telephone: +46 70 410 71 80
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.